PubMed Central
Cure8 research brief
Why This Matters
People with IBD and their clinicians often worry that infections like RSV could be more common or severe because of immune-modifying treatments. This study suggests similar RSV infection rates and largely comparable short-term outcomes between IBD patients and matched non-IBD controls, offering reassurance.
Who Should Pay Attention
Adult patients with IBD, gastroenterology clinicians, and researchers interested in infection risk and vaccine policy for immunocompromised populations.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This nationwide retrospective cohort study used Veterans Health Administration records to compare laboratory-confirmed RSV infections and outcomes between adults with IBD and matched non-IBD controls from 2021–2024.
Incidence of RSV was similar between groups; hospitalization rates were numerically higher in the IBD group but not statistically significant, and ICU admissions were rare. Within the IBD group, RSV-related hospitalization rates did not differ significantly across medication classes in the reported comparisons.
The paper reports most patients had lower exposure to advanced IBD therapies; results may therefore be most applicable to populations with similar treatment patterns.
The study uses chart-adjudicated lab-confirmed RSV and propensity-score matching, which strengthens the comparisons, but as a retrospective VHA cohort it reflects a predominantly older and male population.
Practical takeaways: the authors conclude these results support current RSV vaccination recommendations and offer reassurance that patients with IBD did not have higher RSV incidence or substantially worse short-term outcomes versus matched controls during the study period.
Keep In Mind
The cohort is from the US Veterans Health Administration and is enriched for older male patients; many had lower exposure to advanced biologic therapies, which may limit generalizability to younger or more therapy-exposed IBD populations. Results are observational and report incidence and short-term outcomes (hospitalization, ICU) rather than long-term sequelae.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPubMed Central
JournalInflamm Bowel Dis
AuthorsKhan, Nabeel, Sundararajan, Ramaswamy, Caldera, Freddy +1 more
Indexed viaPubMed Central
Source typeResearch repository record
PublishedJun 23, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Increased risk of respiratory syncytial virus infection in patients with active inflammatory bowel disease: a matched cohort study.
Active IBD was linked to higher risk of RSV infection and more severe respiratory outcomes in this large observational study. That could be relevant for prevention and monitoring during periods of active disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Serious infections in patients with inflammatory bowel disease and corticosteroids: A propensity score-matched study.
Corticosteroid use during IBD treatment periods was associated with higher rates of serious infections across drug classes and age groups, which may affect decisions about steroid use and infection-prevention planning.
Campylobacter spp. infection and subsequent clinical outcomes in patients with inflammatory bowel disease.
This study suggests that a confirmed Campylobacter stool infection in people with IBD was followed by higher rates of flare and need for treatment escalation within 12 months, so infected patients might need closer...